Filippi, S.; Paccosi, E.; Balzerano, A.; Ferretti, M.; Poli, G.; Taborri, J.; Brancorsini, S.; Proietti-De-Santis, L.
CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers 2022, 14, 1687.
https://doi.org/10.3390/cancers14071687
AMA Style
Filippi S, Paccosi E, Balzerano A, Ferretti M, Poli G, Taborri J, Brancorsini S, Proietti-De-Santis L.
CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers. 2022; 14(7):1687.
https://doi.org/10.3390/cancers14071687
Chicago/Turabian Style
Filippi, Silvia, Elena Paccosi, Alessio Balzerano, Margherita Ferretti, Giulia Poli, Juri Taborri, Stefano Brancorsini, and Luca Proietti-De-Santis.
2022. "CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype" Cancers 14, no. 7: 1687.
https://doi.org/10.3390/cancers14071687
APA Style
Filippi, S., Paccosi, E., Balzerano, A., Ferretti, M., Poli, G., Taborri, J., Brancorsini, S., & Proietti-De-Santis, L.
(2022). CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers, 14(7), 1687.
https://doi.org/10.3390/cancers14071687